Open Extension Study Evaluating the Safety and Tolerability of Oral Ziprasidone in the Treatment of Subjects Who Have Successfully Completed a Previous Ziprasidone Study.
Phase of Trial: Phase III
Latest Information Update: 09 Aug 2010
At a glance
- Drugs Ziprasidone (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Pfizer
- 13 Jul 2010 Actual end date added to 1 Jun 2009 as reported by ClinicalTrials.gov.
- 13 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Jun 2009 Actual patient number changed from 329 to 344 as reported by ClinicalTrials.gov.